Cure in Chronic Hepatitis C! Does it Prevent the Risk of Hepatocellular Carcinoma?

Basit Öğe Kaydı
dc.contributor.authorCelen, Mustafa Kemal
dc.contributor.authorAkdemir, Irem
dc.contributor.authorBayan, Kadim
dc.date.accessioned2024-04-24T17:27:53Z
dc.date.available2024-04-24T17:27:53Z
dc.date.issued2018
dc.departmentDicle Üniversitesien_US
dc.description.abstractIn 5%-20% of chronic HCV patients, cirrhosis or other complications like liver cancer may be seen and these may be directly or undirectly related. The development of a sustained viral response (SVR) does not change this fact. In the case of a 52-year-old female diabetic patient whose Anti-HCV was positive, HCV-RNA 2.230.000 IU/mL was decided to be followed up due to an ALT 68 UI/L, AST 55 UI/L. As a result of the biopsy (ISHAK, fibrozis= 2, HAI= 8), Pegile interferon alfa 2a 180 mu g/week + ribavirin 1000 mg/day was started. The patient was put under treatment for 48 weeks and as a result, SVR was obtained and the patient accepted as cure. The patient was told to come for check-up every six months. This patient who had actually started getting better stopped coming to our center in 2015 and did not return for a long time. The patient came back in 2016 with a fatigue complaint. As a result of the examination, AFP was 38.6 and all other parameters were found normal. Although there was no sign of a mass image in her liver ultrasound, there was a hepatocellular carcinoma (HCC) compatible lesion which was 190 x 150 x 90 mm in segment 6-7 in her contrasted MR result. The patient was urgently referred to a transplant center. However, it was determined at the center that since the tumor had made a vein invasion, there was no chance for a transplant. The patient died in June 2017. The cure in HCV treatment does not exclude the reality of HCC, which shows that patients who get the treatment must be followed up very closely. Routine clinical follow up, AFP level screening, effective ultrasound and dynamic imagination are of utmost importance.en_US
dc.identifier.doi10.5578/flora.66528
dc.identifier.endpage87en_US
dc.identifier.issn1300-932X
dc.identifier.issue2en_US
dc.identifier.startpage84en_US
dc.identifier.trdizinid295717
dc.identifier.urihttps://doi.org/10.5578/flora.66528
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/295717
dc.identifier.urihttps://hdl.handle.net/11468/20236
dc.identifier.volume23en_US
dc.identifier.wosWOS:000458961200006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isotren_US
dc.publisherBilimsel Tip Yayinevien_US
dc.relation.ispartofFlora-Infeksiyon Hastaliklari Ve Klinik Mikrobiyoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis C Virusen_US
dc.subjectHepatocellular Carcinomaen_US
dc.titleCure in Chronic Hepatitis C! Does it Prevent the Risk of Hepatocellular Carcinoma?en_US
dc.titleCure in Chronic Hepatitis C! Does it Prevent the Risk of Hepatocellular Carcinoma?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu